To download this report as a PDF file click here.
Bioventix plc
(“Bioventix” or “the Company”)
Director Dealing
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that the Company was notified today that on 29 January 2024 Peter Harrison, Chief Executive Officer of the Company, sold 62,000 ordinary shares of 5 pence each in the Company (“Ordinary Shares”), at a price of 4,200 pence per Ordinary Share (the “Sale”).
The Sale was facilitated to enable a new institutional investor to join the share register. Peter Harrison has undertaken not to dispose of any further Ordinary Shares for 12 months.
Following the Sale, Peter Harrison has a beneficial interest in 297,088 Ordinary Shares, representing approximately 5.7 per cent. of the issued share capital of the Company.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details.
For further information please contact:
|
Bioventix plc Peter Harrison Bruce Hiscock |
Chief Executive Officer Chief Financial Officer |
Tel: 01252 728 001 |
|
|
|
|
|
Cavendish Capital Markets Limited Geoff Nash / Simon Hicks Nigel Birks / Harriet Ward |
Corporate Finance Corporate Broking |
Tel: 020 7220 0500 |
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|
|
a) |
Name |
Peter Harrison |
|
2. |
Reason for the Notification |
|
|
a) |
Position/status |
Chief Executive Officer |
|
b) |
Initial notification/Amendment |
Initial notification |
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
a) |
Name |
Bioventix plc |
|
b) |
LEI |
213800225MHX7LZQY108 |
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a) |
Description of the Financial instrument, type of instrument |
Ordinary Shares of 5 pence each |
|
Identification code |
GB00B4QVDF07 |
|
|
b) |
Nature of the transaction |
Sale of Ordinary Shares |
|
c) |
Price(s) and volume(s) |
62,000 Ordinary Shares 4,200 pence |
|
d) |
Aggregated information:
· Aggregated volume
· Price |
Sale of 62,000 Ordinary Shares at 4,200 pence each |
|
e) |
Date of the transaction |
29 January 2024 |
|
f) |
Place of the transaction |
London Stock Exchange, AIM Market (XLON) |
Bioventix plc
(“Bioventix” or “the Company”)
Director Dealing
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that the Company was notified on 28 November 2023 that on 27 November 2023 Bruce Hiscock, Chief Financial Officer of the Company, purchased a total of 17 ordinary shares of 5 pence each in the Company (“Ordinary Shares”), at an average price of 3,977 pence per Ordinary Share (the “Purchase”). The Ordinary Shares were purchased under a dividend reinvestment plan (“DRIP”).
Following the Purchase, Bruce Hiscock has a beneficial interest in 778 Ordinary Shares, representing approximately 0.01 per cent. of the issued share capital of the Company.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details.
For further information please contact:
|
Bioventix plc Peter Harrison |
Chief Executive Officer |
Tel: 01252 728 001 |
|
Cavendish Capital Markets Limited Geoff Nash / Simon Hicks Nigel Birks / Harriet Ward |
Corporate Finance ECM |
Tel: 020 7220 0500 |
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|
|
a) |
Name |
Bruce Hiscock |
|
2. |
Reason for the Notification |
|
|
a) |
Position/status |
Chief Financial Officer |
|
b) |
Initial notification/Amendment |
Initial notification |
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
a) |
Name |
Bioventix plc |
|
b) |
LEI |
213800225MHX7LZQY108 |
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a) |
Description of the Financial instrument, type of instrument |
Ordinary Shares of 5 pence each |
|
Identification code |
GB00B4QVDF07 |
|
|
b) |
Nature of the transaction |
Purchase of Ordinary Shares |
|
c) |
Price(s) and volume(s) |
17 Ordinary Shares 3,977 pence |
|
d) |
Aggregated information:
· Aggregated volume
· Price |
Purchase of 17 Ordinary Shares at 3,977 pence each |
|
e) |
Date of the transaction |
27 November 2023 |
|
f) |
Place of the transaction |
London Stock Exchange, AIM Market (XLON) |
TR-1: Notification of major interest in shares. To download this report as a PDF file click here.
Bioventix plc (AIM: BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that it has today posted its Annual Report for the year ended 30 June 2023 together with a Notice of Annual General Meeting (“AGM”) and Form of Proxy to shareholders that have elected to receive documentation in hard copy format. The documents will also be available to download in PDF format below:
The Company’s AGM will be held at Farnham Castle, Farnham, Surrey, GU9 0AG on Thursday 7 December 2023 at 2.00pm.
For further information please contact:
|
Bioventix plc |
|
Tel: 01252 728 001 |
|
Cavendish Capital Markets Limited |
|
Tel: 020 7220 0500 |
About Bioventix plc:
Bioventix (www.bioventix.com) specialises in the development and commercial supply of high-affinity monoclonal antibodies with a primary focus on their application in clinical diagnostics, such as in automated immunoassays used in blood testing. The antibodies created at Bioventix are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. Bioventix currently offers a portfolio of antibodies to customers for both commercial use and R&D purposes, for the diagnosis or monitoring of a broad range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. Bioventix currently supplies antibody products and services to the majority of multinational clinical diagnostics companies. Bioventix is based in Farnham, UK and its shares are traded on AIM under the symbol BVXP.
TR-1: Notification of major interest in shares. To download this report as a PDF file click here.
TR-1: Notification of major interest in shares. To download this report as a PDF file click here.
To download this report as a PDF file click here.
Bioventix plc (BVXP) announces its audited results for the year ended 30 June 2023
Highlights:
• Revenue up 9% to £12.82 million (2022: £11.72 million)
• Profit before tax up 9% to £10.13 million (2022: £9.28 million)
• Cash at year end of £5.7 million (30 June 2022: £6.1 million)
• Second interim dividend of 90p per share (2022: 74p)
• Total dividends 152p per share (2022: 152p)
Click here to download the full report.
INTRODUCTION: Detection of Alzheimer’s disease (AD) pathophysiology among indi- viduals with mild cognitive changes and those experiencing subjective cognitive decline (SCD) remains challenging. Plasma phosphorylated tau 217 (p-tau217) is one of the most promising of the emerging biomarkers for AD. However, accessible methods are limited.
METHODS: We employed a novel p-tau217 immunoassay (University of Gothenburg [UGOT] p-tau217) in four independent cohorts (n = 308) including a cerebrospinal fluid (CSF) biomarker-classified cohort (Discovery), two cohorts consisting mostly of cognitively unimpaired (CU) and mild cognitively impaired (MCI) participants (MYHAT and Pittsburgh), and a population-based cohort of individuals with SCD (Barcelonaβeta Brain Research Center’s Alzheimer’s At-Risk Cohort [β-AARC]).
RESULTS: UGOT p-tau217 showed high accuracy (area under the curve [AUC] = 0.80– 0.91) identifying amyloid beta (Aβ) pathology, determined either by Aβ positron emission tomography or CSF Aβ42/40 ratio. In individuals experiencing SCD, UGOT p-tau217 showed high accuracy identifying those with a positive CSF Aβ42/40 ratio (AUC = 0.91).
DISCUSSION: UGOT p-tau217 can be an easily accessible and efficient way to screen and monitor patients with suspected AD pathophysiology, even in the early stages of the continuum.
TR-1: Notification of major interest in shares. To download this report as a PDF file click here.